Clarivate Plc: Morgan Stanley resumes coverage with underweight rating; target price $1.5
CLVT•Morgan Stanley resumed coverage of Clarivate Plc with an underweight rating and a $1.5 target price.
Related News
Pluri partners with ZEO ScientifiX to commercialize regenerative medicine products in US
ZEOX•
Piper Sandler Q3 revenue and profit decline
PIPR•
NextCure to terminate Chief Medical Officer Udayan Guha effective October 31, 2026
NXTC•
Arbor Realty Trust Q3 EPS USD -0.51
ABR•
Nasdaq set for sharp drop as Amazon, Intel amplify AI spending worries
QQQ•